Closed Viral Vector Manufacturing Platforms Global Market Report 2025

The closed viral vector manufacturing platforms market size has grown rapidly in recent years. It will grow from $1.72 billion in 2024 to $1.96 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increasing gene therapy research, rising investment in biopharmaceuticals, higher prevalence of genetic disorders, early adoption of viral vectors, and expanding healthcare expenditure.

The closed viral vector manufacturing platforms market size is expected to see rapid growth in the next few years. It will grow to $3.21 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing demand for viral vectors, need for sterile and scalable production, regulatory support for gene therapies, expansion of cell and gene therapy pipelines, and rising prevalence of chronic diseases. Major trends in the forecast period include integration of automation in manufacturing, adoption of single-use bioreactors, emphasis on process standardization, collaboration between biotech and CDMO companies, and development of high-yield viral production platforms.

The growing number of clinical trials is expected to drive the expansion of the closed viral vector manufacturing platforms market. Clinical trials are carefully designed studies conducted in humans to evaluate the safety, efficacy, and proper use of new medical therapies or interventions. The increasing demand for clinical trials is fueled by the need for innovative treatments, as the prevalence of chronic and complex diseases continues to rise, creating a need for novel therapeutic solutions. Closed viral vector manufacturing platforms facilitate clinical trials by providing consistent, sterile production of viral vectors, ensuring the safety and reliability of the therapies being tested. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI) reported that the total number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023, highlighting the growing demand for such platforms.

Companies in this market are also focusing on developing advanced solutions such as nitro controllers to prevent nitrogen-induced stress or toxicity in cell cultures. Nitro controllers are systems that monitor and regulate nitrogen levels or reactive nitrogen species in bioprocesses, maintaining optimal conditions for cell growth and product formation. In May 2025, Belgium-based Univercells Technologies launched the scale-X nitro controller, a compact and cost-efficient system designed for large-scale viral vector and vaccine production. Compatible with 200 m² and 600 m² scale-X nitro bioreactors, it supports both adherent and suspension cell cultures and enables efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. The system also allows rapid scale-up from research and development to commercial manufacturing within eight months.

In November 2023, Ajinomoto Co., Inc., a Japan-based biotechnology company, acquired Forge Biologics for $545 million. Through this acquisition, Ajinomoto gained Forge’s 200,000-square-foot cGMP facility, the Hearth, in Columbus, Ohio, along with a workforce of over 300 employees. This expansion enhances Ajinomoto’s global gene therapy manufacturing capabilities and strengthens its contract development and manufacturing services for AAV and plasmid-based therapies. Forge Biologics is a US-based company specializing in closed viral vector manufacturing platforms.

Major players in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, and Genesail Biotech Co. Ltd.

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in closed viral vector manufacturing platforms report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The closed viral vector manufacturing platforms market research report is one of a series of new reports that provides closed viral vector manufacturing platforms market statistics, including closed viral vector manufacturing platforms industry global market size, regional shares, competitors with a closed viral vector manufacturing platforms market share, detailed closed viral vector manufacturing platforms market segments, market trends and opportunities, and any further data you may need to thrive in the closed viral vector manufacturing platforms industry. This closed viral vector manufacturing platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Closed viral vector manufacturing platforms are fully enclosed systems designed to produce viral vectors in tightly controlled and sterile environments. They consolidate multiple production steps, including cell growth, vector assembly, purification, and formulation, within a sealed setup to minimize contamination and reduce human intervention. These platforms enhance process consistency, scalability, and regulatory compliance, ensuring high-quality vector production while maintaining safety and efficiency throughout the manufacturing cycle.

The main product types of closed viral vector manufacturing platforms include plasmid DNA, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and others. Plasmid DNA consists of circular, double-stranded DNA molecules that act as essential templates for viral vector production or as direct gene delivery tools in non-viral gene therapy. Key workflows include upstream processing, downstream processing, and fill-finish, and they are applied for gene therapy, vaccines, cell therapy, and other applications. End users include pharmaceutical and biotechnology companies, academic and research institutes, contract manufacturing organizations, and others.

The countries covered in the closed viral vector manufacturing platforms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The closed viral vector manufacturing platforms market includes revenues earned by entities by providing services such as upstream process development, downstream process development, analytical development, and formulation development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.